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Letters
to the Editor
Indications for gadolinium for
coronary angiography
To the Editor:
We read with great interest the article by
Nicolosi and associates1 in the July 2002
issue of the Journal dealing with the ben-
eficial effects of gadolinium on regional
stunning in the canine heart in vivo.
Gadolinium is currently used to en-
hance magnetic resonance imaging and is
known to be well tolerated by the kidneys.
We2 recently reported the first clinical use
of gadolinium for coronary angiography in
a patient with elevated serum creatinine.
We are currently conducting a prospective
randomized trial to evaluate the exact role
as well as the safety of gadolinium for
coronary angiography in patients with ab-
normal renal function. Although none of
our patients had any enzymatic or electro-
cardiographic changes in relation to myo-
cardial damage, we are still wondering
what the exact effects of this drug are on
the myocardium. The article by Nicolosi
and colleagues suggests that gadolinium is
beneficial for the myocardium. This article,
together with the promising results of our
ongoing trial, might pave the way toward
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Reply to the Editor
In response to the letter to the Editor re-
garding our article,1 we find the notion of
using a gadolinium-based contrast agent
for coronary angiography intriguing, par-
ticularly in the context of acute coronary
syndrome. Our study documented the sal-
utary effect of gadolinium chloride (GdCl3),
administered before an ischemic insult, on
contractile function after 3 hours of reper-
fusion. There was no observed effect of
gadolinium on a load-independent index of
contractility in the baseline state, nor were
there effects on heart rate or cardiac output.
The mechanism(s) by which gadolinium
accelerates recovery of contractile function
in stunned myocardium are yet to be deter-
mined. Its may modulate ischemia/reperfu-
sion–induced pathophysiology of intracel-
lular ions, particularly Ca2, via effects on
stretch-activated ion channels, and/or it
may directly attenuate superoxide produc-
tion. These effects, however, have been
observed only with the use of GdCl3. The
gadolinium chelates used as contrast agents
for magnetic resonance imaging and used
by Sarkis and associates3 for coronary an-
giography are generally eliminated by the
kidney unmetabolized. These agents do not
bind plasma proteins, nor are they thought
to react with biologic structures. One can-
not assume that these chelates would exert
effects similar to those of GdCl3. Further
studies of gadolinium chelates would there-
fore be necessary before considering them
for possible dual roles as both contrast
agents and protective agents in coronary
artery disease.
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